Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $185.0 million.

  • Beam Therapeutics' Cash from Investing Activities rose 165.83% to $65.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.6 million, marking a year-over-year decrease of 166.04%. This contributed to the annual value of $185.0 million for FY2024, which is 157.53% up from last year.
  • As of FY2024, Beam Therapeutics' Cash from Investing Activities stood at $185.0 million, which was up 157.53% from $71.8 million recorded in FY2023.
  • Beam Therapeutics' Cash from Investing Activities' 5-year high stood at $185.0 million during FY2024, with a 5-year trough of -$461.3 million in FY2022.
  • Over the past 3 years, Beam Therapeutics' median Cash from Investing Activities value was $71.8 million (recorded in 2023), while the average stood at -$68.2 million.
  • Per our database at Business Quant, Beam Therapeutics' Cash from Investing Activities tumbled by 193.78% in 2021 and then spiked by 157.53% in 2024.
  • Yearly analysis of 5 years shows Beam Therapeutics' Cash from Investing Activities stood at -$100.1 million in 2020, then tumbled by 193.78% to -$294.1 million in 2021, then plummeted by 56.84% to -$461.3 million in 2022, then spiked by 115.57% to $71.8 million in 2023, then spiked by 157.53% to $185.0 million in 2024.